Proteomic evaluation of biological nanoparticles isolated from human kidney stones and calcified arteries.
Calcifying biological nanoparticles (NPs) develop under cell culture conditions from homogenates of diverse tissue samples displaying extraosseous mineralization, including kidney stones and calcified aneurysms. Probes to definitively identify NPs in biological systems are lacking. Therefore, the aim of this study was to begin to establish a proteomic biosignature of NPs in order to facilitate more definitive investigation of their contribution to disease. Biological NPs derived from human kidney stones and calcified aneurysms were completely decalcified by overnight treatment with ethylenediaminetetraacetic acid or brief incubation in HCl, as evidenced by lack of a calcium shell and of Alizarin Red S staining, by transmission electron microscopy and confocal microscopy, respectively. Decalcified NPs contained numerous proteins, including some from bovine serum and others of prokaryotic origin. Most prominent of the latter group was EF-Tu, which appeared to be identical to EF-Tu from Staphylococcus epidermidis. A monoclonal antibody against human EF-Tu recognized a protein in Western blots of total NP lysate, as well as in intact NPs by immunofluorescence and immunogold EM. Approximately 8% of NPs were quantitatively recognized by the antibody using flow cytometry. Therefore, we have defined methods to reproducibly decalcify biological NPs, and identified key components of their proteome. These elements, including EF-Tu, can be used as biomarkers to further define the processes that mediate propagation of biological NPs and their contribution to disease.
Shiekh
Farooq A
FA
Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Charlesworth
Jon E
JE
Kim
Sung-Hoon
SH
Hunter
Larry W
LW
Jayachandran
Muthuvel
M
Miller
Virginia M
VM
Lieske
John C
JC
D000595:Amino Acid Sequence; D000818:Animals; D001158:Arteries / Q000473:pathology*; D015415:Biomarkers / Q000378:metabolism; D002114:Calcinosis / Q000473:pathology*; D002417:Cattle; D006801:Humans; D007669:Kidney Calculi / Q000737:chemistry*; D008969:Molecular Sequence Data; D053758:Nanoparticles / Q000032:analysis*; D010444:Peptide Elongation Factor Tu / Q000235:genetics / Q000378:metabolism; D020543:Proteome / Q000032:analysis*
D015415:Biomarkers; D020543:Proteome; D010444:Peptide Elongation Factor Tu
Urol Res. 2004 Jun;32(3):190-5
15205851
J Investig Med. 2006 Nov;54(7):412-24
17169263
Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1434-41
19286948
J Investig Med. 2006 Nov;54(7):367-79
17169258
Proc Natl Acad Sci U S A. 1978 Mar;75(3):1250-4
349562
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8274-9
9653177
PLoS Pathog. 2008 Feb 8;4(2):e41
18282102
Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1115-24
15142839
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11511-5
11027350
Nanomedicine (Lond). 2009 Dec;4(8):931-41
19958229
Science. 2006 Feb 3;311(5761):622-7
16456071
PLoS One. 2009;4(2):e4417
19198665
Int J Nanomedicine. 2008;3(2):243-8
18686783
J Bacteriol. 2000 Dec;182(24):6913-20
11092850
Nature. 1976 May 6;261(5555):23-6
775340